Anthracycline + Cyclophosphamide + Docetaxel + Capecitabine

This is a combination chemotherapy regimen that includes four distinct agents: 1. **Anthracyclines** (such as doxorubicin or epirubicin) - These drugs work by intercalating with DNA and interfering with DNA metabolism and RNA production. They damage cancer cell DNA by inhibiting topoisomerase II, preventing cancer cells from reproducing. 2. **Cyclophosphamide** - An alkylating agent that damages DNA by adding alkyl groups to DNA bases, preventing cell division. 3. **Docetaxel** - A taxane drug that works by disrupting microtubule function, which is essential for cell division. 4. **Capecitabine** - An oral fluoropyrimidine that converts to 5-fluorouracil in tumor tissues, interfering with DNA synthesis. ## Clinical Use This combination regimen is typically used in the treatment of various cancers, particularly: - Breast cancer - Potentially other solid tumors ## Side Effects The combination may cause a range of side effects due to the individual components: - **Anthracycline-related**: Cardiotoxicity (heart damage), which can be acute or delayed and potentially lead to heart failure; red or pink urine; nausea; vomiting; hair loss; and decreased bone marrow function. - **General chemotherapy side effects**: Fatigue, nausea, vomiting, hair loss, decreased blood cell counts, and increased risk of infection. The anthracycline component in particular carries a lifetime cumulative dose limit due to the risk of permanent heart damage. ## Administration This combination would typically be administered as: - Anthracycline and cyclophosphamide: Intravenous - Docetaxel: Intravenous - Capecitabine: Oral tablets The specific dosing schedule would depend on the cancer type, stage, and patient factors. This combination represents an aggressive multi-modal approach to cancer treatment, targeting different aspects of cancer cell division and growth through complementary mechanisms of action.